Ambrx Biopharma Inc (AMAM)

[Hercules1]

$AMAM:

potentially a multi billion dollar drug here folks:


we are probably looking at a $50 to $70 dollar stock in time here.



The preliminary results showed a 51.7% overall response rate (ORR) and 100% disease control rate (DCR) following treatment with ARX788. Additionally, no drug-related serious adverse events (SAEs) were noted by any patients.

With investors reacting the way they did, it’s safe to say they were impressed with the results; considering how big the breast cancer market is, the drug’s potential has caused a bit of a stir.